PL2251330T3 - 4-hydroksybenzomorfany - Google Patents

4-hydroksybenzomorfany

Info

Publication number
PL2251330T3
PL2251330T3 PL10008474T PL10008474T PL2251330T3 PL 2251330 T3 PL2251330 T3 PL 2251330T3 PL 10008474 T PL10008474 T PL 10008474T PL 10008474 T PL10008474 T PL 10008474T PL 2251330 T3 PL2251330 T3 PL 2251330T3
Authority
PL
Poland
Prior art keywords
hydroxybenzomorphans
thiocarboxamide
antitussives
anticonvulsants
analgesics
Prior art date
Application number
PL10008474T
Other languages
English (en)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of PL2251330T3 publication Critical patent/PL2251330T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
PL10008474T 2004-11-05 2005-11-03 4-hydroksybenzomorfany PL2251330T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
EP10008474A EP2251330B1 (en) 2004-11-05 2005-11-03 4-Hydroxybenzomorphans
EP05851351A EP1817291A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (1)

Publication Number Publication Date
PL2251330T3 true PL2251330T3 (pl) 2012-12-31

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10008474T PL2251330T3 (pl) 2004-11-05 2005-11-03 4-hydroksybenzomorfany

Country Status (20)

Country Link
US (7) US7262298B2 (pl)
EP (2) EP1817291A1 (pl)
JP (3) JP5198067B2 (pl)
KR (1) KR101115841B1 (pl)
CN (1) CN101090891B (pl)
AT (1) ATE557006T1 (pl)
AU (1) AU2005304950B2 (pl)
BR (1) BRPI0517091B8 (pl)
CA (1) CA2587074C (pl)
CY (1) CY1112946T1 (pl)
DK (1) DK2251330T3 (pl)
ES (1) ES2387737T3 (pl)
IL (1) IL182983A (pl)
MX (1) MX2007005389A (pl)
NO (1) NO340204B1 (pl)
PL (1) PL2251330T3 (pl)
PT (1) PT2251330E (pl)
RU (2) RU2415131C2 (pl)
SI (1) SI2251330T1 (pl)
WO (1) WO2006052710A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2006052710A1 (en) * 2004-11-05 2006-05-18 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
US7557119B2 (en) 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
CA2637610A1 (en) 2007-05-04 2008-11-04 Mallinckrodt Inc. Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
JP2010533719A (ja) 2007-07-17 2010-10-28 マリンクロッド・インコーポレイテッド 還元的アミノ化によるｎ−アルキル化オピエートの調製
CA2694497C (en) 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
NZ592005A (en) 2008-09-30 2013-03-28 Mallinckrodt Llc Process for the preparation of a N-alkylated ketomorphinan by selective catalytiC hydrogen transfer reduction
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
JP5555890B2 (ja) * 2009-03-19 2014-07-23 アルカーメス ファーマ アイルランド リミテッド 高い経口バイオアベイラビリティを有するモルフィナン誘導体
WO2010118274A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-keto, 3-alkoxy morphinans
CN102803267A (zh) 2009-06-11 2012-11-28 马林克罗特有限公司 通过催化氢转移的6-α-氨基N-取代的吗啡喃的制备
EP2440561B1 (en) 2009-06-11 2014-04-30 Mallinckrodt LLC Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
SI2506712T1 (sl) * 2009-12-04 2019-06-28 Alkermes Pharma Ireland Limited, Derivati morfinana za zdravljenje prevelikega odmerka mamil
AU2011232628B2 (en) 2010-03-22 2015-04-09 Rensselaer Polytechnic Institute Morphinane derivatives containing a carboxamide group as opioid receptor ligands
ES2527315T3 (es) * 2010-04-29 2015-01-22 Mallinckrodt Llc Preparación de compuestos morfinano con cetona saturada que tienen un bajo contenido en metal
ES2708726T3 (es) 2010-07-08 2019-04-10 Alkermes Pharma Ireland Ltd Proceso para la síntesis de morfinanos sustituidos
DK2608670T3 (en) 2010-08-23 2019-02-11 Alkermes Pharma Ireland Ltd METHOD OF TREATING ANTI-SOCIETY-INDICATED WEIGHT RISE
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
US9296699B2 (en) 2011-06-09 2016-03-29 Mallinckrodt Llc Reductive amination of 6-keto morphinans by catalytic hydrogen transfer
JP5981992B2 (ja) 2011-06-29 2016-08-31 アルカーメス，インコーポレイテッド 末梢作用オピオイド化合物
CA2845187A1 (en) 2011-09-08 2013-03-14 Peter X. Wang Production of alkaloids without the isolation of intermediates
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3415148A1 (en) 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
NZ631018A (en) * 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
JPWO2018159716A1 (ja) * 2017-03-02 2019-12-26 株式会社三和化学研究所 アルコール使用障害の治療薬
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
CN113248435B (zh) * 2020-02-13 2024-06-04 上海翰森生物医药科技有限公司 3-甲酰胺基-4-羟基纳曲酮氘代衍生物、其制备方法及其在医药上的应用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN114621238A (zh) * 2020-12-10 2022-06-14 鲁南制药集团股份有限公司 一种制备纳呋拉啡的方法
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
SU635868A3 (ru) * 1974-11-12 1978-11-30 Бристол Мейерз Компани (Фирма) Способ получени морфиновых производных или их солей
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
WO2006052710A1 (en) * 2004-11-05 2006-05-18 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans

Also Published As

Publication number Publication date
IL182983A0 (en) 2007-08-19
US8802655B2 (en) 2014-08-12
EP2251330A1 (en) 2010-11-17
US20070238748A1 (en) 2007-10-11
CN101090891B (zh) 2012-08-01
SI2251330T1 (sl) 2012-09-28
US20060111384A1 (en) 2006-05-25
RU2010147915A (ru) 2012-05-27
RU2415131C2 (ru) 2011-03-27
CA2587074A1 (en) 2006-05-18
MX2007005389A (es) 2007-12-07
WO2006052710A1 (en) 2006-05-18
EP2251330B1 (en) 2012-05-09
RU2480455C2 (ru) 2013-04-27
US20130231361A1 (en) 2013-09-05
PT2251330E (pt) 2012-07-20
JP2013067636A (ja) 2013-04-18
JP2016020364A (ja) 2016-02-04
CY1112946T1 (el) 2016-04-13
BRPI0517091B1 (pt) 2019-10-08
US20150011768A1 (en) 2015-01-08
US20240092740A1 (en) 2024-03-21
US7262298B2 (en) 2007-08-28
RU2007120759A (ru) 2008-12-10
BRPI0517091A (pt) 2008-09-30
JP5198067B2 (ja) 2013-05-15
ATE557006T1 (de) 2012-05-15
AU2005304950B2 (en) 2010-12-09
NO20072839L (no) 2007-08-03
KR20070085723A (ko) 2007-08-27
CN101090891A (zh) 2007-12-19
KR101115841B1 (ko) 2012-03-09
JP2008519035A (ja) 2008-06-05
JP6058981B2 (ja) 2017-01-11
EP1817291A1 (en) 2007-08-15
US20140148475A1 (en) 2014-05-29
IL182983A (en) 2012-06-28
US8680112B2 (en) 2014-03-25
BRPI0517091B8 (pt) 2021-05-25
AU2005304950A1 (en) 2006-05-18
ES2387737T3 (es) 2012-10-01
CA2587074C (en) 2012-09-04
DK2251330T3 (da) 2012-08-06
US20160075658A1 (en) 2016-03-17
NO340204B1 (no) 2017-03-20

Similar Documents

Publication Publication Date Title
IL182983A0 (en) 4-hydroxybenzomorphans
USD782698S1 (en) Rail
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
WO2006081273A8 (en) 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
IL174635A0 (en) Fibrosis-inducing agents, compositions containing the same and intravascular devices containing the same
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
PL1651042T3 (pl) Kompozycja chwastobójcza o zwiększonym działaniu chwastobójczym i sposób zwiększania działania chwastobójczego
EG25097A (en) Piprazinyl and diazapanyl benzamides and benzthioamides.
GB0409558D0 (en) Particulate emulsifiers,emulsions and uses thereof
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
WO2004031352A3 (en) Interferon variants with improved properties
AP2005003461A0 (en) Sonic heads and assemblies and uses thereof.
ZA200500219B (en) Modified bryodin 1 with reduced immunogenicity.
HRP20040691A2 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug
ZA200408787B (en) Pharmaceutical combination.
GB0428306D0 (en) Compound
ITBO20040403A1 (it) Riduttore di velocita', particolarmente per estrusori, e simili
EP1829860A4 (en) 9,10-SECOPREGNANDERIVAT AND MEDICINE
AU2003216893A1 (en) Phenethylacrylamide, methods for the production thereof and agents containing the same
PL114818U1 (en) V .03
ZA200201853B (en) Homogeniser.
ITGE20030111A1 (it) Anta, in particolare per armadi e simili.
ITPD20030307A1 (it) Slamatore con bloccaggio dell'amo
GB0216172D0 (en) Text 3